Q4 2024 ALK-Abello A/S Earnings Call Transcript
Key Points
- Revenue grew by 11% in Q4, with Europe showing strong performance and double-digit sales growth across all product lines.
- European tablet sales increased by 32%, solidifying market momentum.
- 2024 was a record year for Alk-Abello AS (AKBLF), with revenue up 15% and earnings improving by 65% in local currencies.
- The company successfully executed its LG plus strategy, expanding into new therapy areas and unlocking potential in existing markets.
- ALK's gross margin improved to 64.2%, driven by volume growth, sales mix changes, improved pricing, and production efficiencies.
- North America and international markets did not contribute to top-line growth in Q4.
- Revenue growth was lower than in Q2 and Q3 due to anticipated factors.
- Q4 operating margin was impacted by one-off costs, ending at 14%.
- Free cash flow was negative at DKK204 million due to an upfront payment related to the Neffy license deal.
- Revenue in North America remained unchanged, with some product sales declining.
/-- -
Hello everyone and welcome to this presentation of ALK's full year results and the outlook for '25 and thank you all for joining us. Let's turn to slide number 2 with an introduction to the agenda and the speakers.
My name is Per Plotnikof. I'm head of investor relations, and with me today are CEO Peter Halling and CFO Claus Steensen Sølje.
We'll first be sharing highlights from Q4 in the full year. Then we'll take a closer look at the market and product trends as well as the financials. We will also provide an update on the execution of the [LG] strategy before we present the outlook. As usual, we will end the presentation with a Q&A session and to get us started, I'll hand you over to Peter and slide number 3 for the Q4 and full year highlights. Please go ahead.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
